Glukoza Viaflo Baxter (Glucose)

Glukoza Viaflo Baxter is indicated for several clinical situations where rapid carbohydrate delivery and fluid replacement are required.

• Treatment of acute hypoglycemia in hospital settings.
• Fluid and electrolyte replacement during dehydration or postoperative care.
• Component of parenteral nutrition regimens for patients unable to eat orally.
• Intra‑operative glucose support to maintain blood sugar levels.
• Management of metabolic needs in critically ill patients.
• Support for patients with impaired oral intake or gastrointestinal dysfunction.

Glukoza Viaflo Baxter may be associated with a range of adverse reactions, most of which are related to its glucose content and intravenous administration.

Common

• Transient hyperglycemia or elevated blood glucose levels.
• Local irritation or phlebitis at the infusion site.
• Mild nausea or gastrointestinal discomfort.
• Electrolyte disturbances such as mild hyponatremia.
• Fluid overload in patients with limited cardiac reserve.

Serious

• Severe hyperglycemia requiring medical intervention.
• Anaphylactic or severe allergic reactions.
• Metabolic acidosis in susceptible individuals.
• Cardiac arrhythmias secondary to electrolyte shifts.
• Pulmonary edema from excessive fluid administration.

When using Glukoza Viaflo Baxter, clinicians should observe several safety considerations to minimize risk.

• Monitor blood glucose levels frequently, especially in diabetic patients.
• Assess fluid status and cardiac function to avoid volume overload.
• Adjust infusion rates in patients with renal or hepatic impairment.
• Review electrolyte balance regularly during prolonged therapy.
• Use with caution in pregnancy and lactation, as safety data are limited.
• Pediatric administration should be performed under specialist supervision.
• Ensure proper aseptic technique to reduce infection risk at the infusion site.

Glukoza Viaflo Baxter can interact with other medications or therapies that affect glucose metabolism or fluid balance.

Avoid

• Simultaneous high‑dose insulin therapy without dose adjustment, as it may precipitate severe hypoglycemia.
• Co‑administration with other hyperglycemic agents that could cause uncontrolled hyperglycemia.

Use with caution

• Diuretics, which may exacerbate electrolyte disturbances.
• Corticosteroids, which can increase blood glucose levels.
• Beta‑adrenergic agonists, which may raise glucose concentrations.
• Other intravenous fluids, to prevent cumulative fluid overload.
• Electrolyte solutions, to maintain appropriate serum electrolyte concentrations.